The absence of interaction between drug metabolizing enzyme genotypes and maternal lifestyle factors on glycophorin A somatic mutation frequency levels in newborns.

2.50
Hdl Handle:
http://hdl.handle.net/10146/56957
Title:
The absence of interaction between drug metabolizing enzyme genotypes and maternal lifestyle factors on glycophorin A somatic mutation frequency levels in newborns.
Authors:
Nukui, Tomoko; Day, Richard D.; Gordish-Dressman, Heather A.; Harger, Gail; Bigbee, William L.; Ness, Roberta B.; Romkes, Marjorie
Abstract:
Prenatal exposure to carcinogens results in newborn DNA damage which in turn is associated with impaired health conditions in both childhood and adulthood. The present study aimed to evaluate whether phase I and II biotransformation enzyme genetic polymorphisms in combination with environmental exposures during pregnancy result in elevated levels of newborn DNA damage. Maternal peripheral and umbilical cord blood samples from 406 mother/newborn pairs were genotyped for a panel of phase I/II metabolic enzymes (CYP1A1, CYP2E1, GSTM1, GSTT1 and NAT2) responsible for the metabolism of tobacco and lifestyle-related mutagens and carcinogens. DNA damage was measured by somatic cell mutation frequency at the glycophorin A (GPA) locus in newborns. No association with elevated somatic cell mutation frequency was observed between the combination of maternal/newborn genotypes and cigarette smoke or lifestyle exposures. The observed variation in newborn GPA frequency might be due to either environmental factors not assessed in this study or inter-individual differences in alternative metabolic or DNA repair pathways.
Citation:
Pharmacogenet. Genomics 2006, 16 (2):129-138
Journal:
Pharmacogenetics and genomics
Issue Date:
Feb-2006
URI:
http://hdl.handle.net/10146/56957
PubMed ID:
16424825
Additional Links:
http://www.jpharmacogenetics.com/pt/re/pharmgen/abstract.01213011-200602000-00007.htm;jsessionid=JLrc3YrxLySCtJybR9pMlbQZY7t0MLKR9grQM11fwCPLGwhkBFZr!-269263472!181195628!8091!-1
Type:
Article
Language:
en
Description:
. Biomarkers of exposure & early effects: field studiesBiomarker: mutation frequency of glycophorin AExposure/effect represented: cigarette smoke/ DNA damageStudy design: cross-sectionalStudy size: 2405 pregnant womenAnalytical technique: The GPA somatic cell mutation assayTissue/biological material/sample size: peripheral bloodImpact on outcome (including dose-response): active smoker/non-smoker a positive significant overall association of smoking with a newborn Ψ/N Vf was observed by generalized linear model analysis (P=0.023)Quality control: reliability of maternal self-reported cigarette smoking was verified by measuring cotinine levels in maternal blood samples in a separate analysisBiomarkers of individual susceptibility: field studiesBiomarker (including alleles if genetic): CYP1A1*2A, CYP1A1*3, CYP2E1*5B, NAT2*5, *6A, *7A and *14A, GSTM1 and GSTT1Effect studied (phenotype/pathology): DNA damageMethod of analysis: RFLP-PCRImpact on outcome (including dose-response): CYP1A1* 2A or CYP1A1*3, 33.6%; CYP2E1*5B, 6.9%; GSTM1 null, 46.8%; GSTT1 null, 24.1%; and NAT2 slow, 43.1%. KEYWORDS CLASSIFICATION: Adolescent;Adult;Alleles;biomarkers of exposure & effect: field studies;biomarkers of individual susceptibility: field studies;blood;Female;Fetal Blood;genetics;Genotype;Glycophorin;Humans;Infant,Newborn;metabolism;methods;Maternal-Fetal Exchange;Mothers;Mutation;Pharmacogenetics;Polymorphism,Genetic;Pregnancy;Research;Smoking.
ISSN:
1744-6872
Appears in Collections:
Articles with annotation

Full metadata record

DC FieldValue Language
dc.contributor.authorNukui, Tomoko-
dc.contributor.authorDay, Richard D.-
dc.contributor.authorGordish-Dressman, Heather A.-
dc.contributor.authorHarger, Gail-
dc.contributor.authorBigbee, William L.-
dc.contributor.authorNess, Roberta B.-
dc.contributor.authorRomkes, Marjorie-
dc.date.accessioned2009-03-24T09:47:33Z-
dc.date.available2009-03-24T09:47:33Z-
dc.date.issued2006-02-
dc.identifier.citationPharmacogenet. Genomics 2006, 16 (2):129-138en
dc.identifier.issn1744-6872-
dc.identifier.pmid16424825-
dc.identifier.urihttp://hdl.handle.net/10146/56957-
dc.description. Biomarkers of exposure & early effects: field studiesBiomarker: mutation frequency of glycophorin AExposure/effect represented: cigarette smoke/ DNA damageStudy design: cross-sectionalStudy size: 2405 pregnant womenAnalytical technique: The GPA somatic cell mutation assayTissue/biological material/sample size: peripheral bloodImpact on outcome (including dose-response): active smoker/non-smoker a positive significant overall association of smoking with a newborn Ψ/N Vf was observed by generalized linear model analysis (P=0.023)Quality control: reliability of maternal self-reported cigarette smoking was verified by measuring cotinine levels in maternal blood samples in a separate analysisBiomarkers of individual susceptibility: field studiesBiomarker (including alleles if genetic): CYP1A1*2A, CYP1A1*3, CYP2E1*5B, NAT2*5, *6A, *7A and *14A, GSTM1 and GSTT1Effect studied (phenotype/pathology): DNA damageMethod of analysis: RFLP-PCRImpact on outcome (including dose-response): CYP1A1* 2A or CYP1A1*3, 33.6%; CYP2E1*5B, 6.9%; GSTM1 null, 46.8%; GSTT1 null, 24.1%; and NAT2 slow, 43.1%. KEYWORDS CLASSIFICATION: Adolescent;Adult;Alleles;biomarkers of exposure & effect: field studies;biomarkers of individual susceptibility: field studies;blood;Female;Fetal Blood;genetics;Genotype;Glycophorin;Humans;Infant,Newborn;metabolism;methods;Maternal-Fetal Exchange;Mothers;Mutation;Pharmacogenetics;Polymorphism,Genetic;Pregnancy;Research;Smoking.en
dc.description.abstractPrenatal exposure to carcinogens results in newborn DNA damage which in turn is associated with impaired health conditions in both childhood and adulthood. The present study aimed to evaluate whether phase I and II biotransformation enzyme genetic polymorphisms in combination with environmental exposures during pregnancy result in elevated levels of newborn DNA damage. Maternal peripheral and umbilical cord blood samples from 406 mother/newborn pairs were genotyped for a panel of phase I/II metabolic enzymes (CYP1A1, CYP2E1, GSTM1, GSTT1 and NAT2) responsible for the metabolism of tobacco and lifestyle-related mutagens and carcinogens. DNA damage was measured by somatic cell mutation frequency at the glycophorin A (GPA) locus in newborns. No association with elevated somatic cell mutation frequency was observed between the combination of maternal/newborn genotypes and cigarette smoke or lifestyle exposures. The observed variation in newborn GPA frequency might be due to either environmental factors not assessed in this study or inter-individual differences in alternative metabolic or DNA repair pathways.en
dc.language.isoenen
dc.relation.urlhttp://www.jpharmacogenetics.com/pt/re/pharmgen/abstract.01213011-200602000-00007.htm;jsessionid=JLrc3YrxLySCtJybR9pMlbQZY7t0MLKR9grQM11fwCPLGwhkBFZr!-269263472!181195628!8091!-1en
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAlleles-
dc.subject.meshFemale-
dc.subject.meshFetal Blood-
dc.subject.meshGenotype-
dc.subject.meshGlycophorin-
dc.subject.meshHumans-
dc.subject.meshInfant, Newborn-
dc.subject.meshMaternal-Fetal Exchange-
dc.subject.meshMothers-
dc.subject.meshMutation-
dc.subject.meshPharmacogenetics-
dc.subject.meshPolymorphism, Genetic-
dc.subject.meshPregnancy-
dc.subject.meshSmoking-
dc.titleThe absence of interaction between drug metabolizing enzyme genotypes and maternal lifestyle factors on glycophorin A somatic mutation frequency levels in newborns.en
dc.typeArticleen
dc.identifier.journalPharmacogenetics and genomicsen

Related articles on PubMed

All Items in ECNIS-NIOM are protected by copyright, with all rights reserved, unless otherwise indicated.